18 min
Big announcement and Hepatic impairment studies (Ep. 22) Clinical Pharmacology Podcast with Nathan Teuscher
-
- Life Sciences
Today’s show is about hepatic impairment clinical studies. I cover the rationale behind evaluating hepatic impairment, common study designs, and key factors in the analysis and interpretation of the study results. I also share a huge announcement about Aplos NCA, a cloud-based solution for calculating NCA PK parameters. Use the link below to learn more about Aplos NCA.
Links discussed in the show:
FDA guidance
EMA guideline
Aplos Analytics website
You can connect with me on LinkedIn and send me a message
Send me a message
Sign up for my newsletter
Copyright Teuscher Solutions LLC
Today’s show is about hepatic impairment clinical studies. I cover the rationale behind evaluating hepatic impairment, common study designs, and key factors in the analysis and interpretation of the study results. I also share a huge announcement about Aplos NCA, a cloud-based solution for calculating NCA PK parameters. Use the link below to learn more about Aplos NCA.
Links discussed in the show:
FDA guidance
EMA guideline
Aplos Analytics website
You can connect with me on LinkedIn and send me a message
Send me a message
Sign up for my newsletter
Copyright Teuscher Solutions LLC
18 min